Suresh Anaganti

BAY 43-9006 Inhibition of Oncogenic RET Mutants

Francesca Carlomagno, Suresh Anaganti, Teresa Guida et al. · JNCI Journal of the National Cancer Institute · 2006 · 471 citations · Full text

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors

Francesca Carlomagno, Teresa Guida, Suresh Anaganti et al. · Oncogene · 2004 · 252 citations

Signal Transduction, Receptor Tyrosine Kinase, Genetics +7

Sorafenib Inhibits Imatinib-Resistant KIT and Platelet-Derived Growth Factor Receptor β Gatekeeper Mutants

Teresa Guida, Suresh Anaganti, Livia Provitera et al. · Clinical Cancer Research · 2007 · 72 citations · Full text

Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474

Francesca Carlomagno, Teresa Guida, Suresh Anaganti et al. · Endocrine Related Cancer · 2008 · 40 citations · Full text

Molecular Biology, Molecular Pharmacology, Signaling Pathway +16

p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines

Lynnette Fernandez‐Cuesta, Suresh Anaganti, Pierre Hainaut et al. · International Journal of Cancer · 2010 · 39 citations · Full text

P53 Status, Breast Oncology, Pathology +16